ClinicalTrials.gg
RecruitingNCT05940142Propo2022Updated Jul 11, 2023

Prediction of Propofol Effect Compartment Concentrations

An observational study in Analysis of Anaesthesia Depth, sponsored by Karl Landsteiner University of Health Sciences. Recruiting at 1 site in Austria. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-11.

Sponsored by Karl Landsteiner University of Health Sciences · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to learn about the prediction of the effect of Propofol by means of EEGs. The main questions it aims to answer are:

  • Develop models that can reliably predict the effect of Propofol
  • Select the most well suited model for clinical practice
  • Compare this model to already existing models (e.g. Schnider-model)

Participants will asked to allow us to collect and use the EEG data recorded during the operations.

02

Conditions studied

  • Analysis of Anaesthesia Depth
03

In context

Lead sponsor

Karl Landsteiner University of Health Sciences is the lead sponsor of 13 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All patients meeting the inclusion and exclusion criteria

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age of 18 or older at the time of the signature of the
  • Signed informed consents
  • Planned TIVA with Propofol

Exclusion criteria

Exclusion Criteria:

  • Use of extracorporal circulation (e.g., HLM, ECMO)
  • Admission to an ICU/IMCU before the operation or planned admission to an ICU/IMCU after the operation
  • Administration of Propofol seven days prior to the planned operation
  • Missing
  • All against TIVA (e.g., allergy against Propofol or soy)
  • All operations where BIS monitoring cannot be used (e.g., skin lesions on the front)
  • Patients for which the administration of Propofol could be potentially harmfull (e.g., severe heart failure with the risk of drop of blood pressure)
  • Neurosurgical operations
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Bilateral BIS values (derived from EEG)

    Comparison of Predicted and Measured EEG values (recorded every five seconds)

    Time frame: During procedure (From the beginning of general anaesthesia (induction of anaesthesia) until the patient has woken up (end of anaesthesia)).

  2. Propofol cumulative dose

    Cumulative dose of Propofol (recorded every second)

    Time frame: During procedure (From the beginning of general anaesthesia (induction of anaesthesia) until the patient has woken up (end of anaesthesia)).

07

Study locations

1 of 1 sites recruiting
  • Klinische Abteilung für Anästhesie und Intensivmedizin
    Krems, Niederösterreich 3500, Austria
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2023 (actual). Primary completion is estimated for Dec 2024, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2023
First posted
Jul 11, 2023
StartActual
May 1, 2023
Primary completionEst.
Dec 31, 2024
CompletionEst.
May 31, 2025
Last update
Jul 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05940142
Lead sponsor
Karl Landsteiner University of Health Sciences
Responsible party
Sponsor
First posted
Jul 11, 2023
Start date
May 1, 2023
Primary completion
Dec 31, 2024 (estimated)
Completion
May 31, 2025 (estimated)
Last update
Jul 11, 2023

Study contacts

Robert Fritze, MD
Contact
Robert.Fritze@krems.lknoe.at
++43/2732/9004-14055

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion